Edition:
United States

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

32.68USD
22 May 2017
Change (% chg)

-- (--)
Prev Close
$32.68
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
575,120
52-wk High
$63.73
52-wk Low
$14.84

Latest Key Developments (Source: Significant Developments)

Paulson & Co Inc takes share stake in Amazon, Arconic - SEC filing
Monday, 15 May 2017 05:33pm EDT 

May 15 (Reuters) - Paulson & Co Inc : :Paulson & Co Inc takes share stake in Amazon of 5,500 shares - SEC filing.Paulson & Co Inc takes share stake of 983,300 shares in Arconic Inc.Paulson & Co Inc takes share stake of 78,101 shares in Sarepta Therapeutics Inc.Paulson & Co Inc ups share stake in Glaxosmithkline PLC by 40.2 percent to 415,100 Sponsored ADR.Paulson & Co Inc - Change in holdings are as of March 31, 2017 and compared with the previous quarter ended as of Dec 31, 2016.  Full Article

Summit Therapeutics says completes enrolment of PhaseOut DMD
Monday, 15 May 2017 07:00am EDT 

May 15 (Reuters) - Summit Therapeutics Plc :Summit completes enrolment of PhaseOut DMD, a phase 2 clinical trial of ezutromid in patients with dmd.Summit Therapeutics - with dosing of last patient in trial, co has triggered $22 million milestone payment.$22 million milestone payment is part of company's licence and collaboration agreement with Sarepta Therapeutics Inc.  Full Article

Sarepta Therapeutics says CEO Edward Kaye intends to resign
Thursday, 27 Apr 2017 05:19pm EDT 

April 27 (Reuters) - Sarepta Therapeutics Inc -:Sarepta Therapeutics Inc - on April 24, Edward M. Kaye president, chief executive officer informed board of his intention to resign - sec filing.Sarepta - CEO Edward M. Kaye informed board of intention to resign upon conclusion of current employment term on sept 20, or some other future date.Sarepta Therapeutics Inc - Kaye will continue to serve as a director following his resignation as president and chief executive officer.  Full Article

Sarepta Therapeutics anticipates net revenues for the year to exceed $95 mln
Thursday, 27 Apr 2017 04:01pm EDT 

April 27 (Reuters) - Sarepta Therapeutics Inc -:Sarepta Therapeutics - in Q1, recognized net revenues of $16.3 million in product sales; no revenue was recognized for the same period of 2016.Sarepta Therapeutics - company anticipates net revenues for the year will exceed $95 million.  Full Article

Sarepta Therapeutics Q4 non-gaap loss per share $0.71
Tuesday, 28 Feb 2017 04:03pm EST 

Sarepta Therapeutics Inc : Sarepta Therapeutics announces fourth quarter and full-year 2016 financial results and recent corporate developments . Q4 non-gaap loss per share $0.71 . Q4 earnings per share view $-1.33 -- Thomson Reuters I/B/E/S . Sarepta Therapeutics Inc - qtrly total revenues $5.4 million versus $1.3 million . Sarepta Therapeutics Inc says in 2017, focused on executing a successful launch of exondys 51 in US . Q4 revenue view $4.7 million -- Thomson Reuters I/B/E/S .Sarepta - Q4 incremental loss primarily driven by expense recorded in connection with an up-front payment of $40.0 million related to license agreement with Summit Therapeutics.  Full Article

Sarepta Therapeutics agrees to sale of priority review voucher for $125 mln
Tuesday, 21 Feb 2017 07:00am EST 

Sarepta Therapeutics Inc : Sarepta Therapeutics agrees to sale of priority review voucher for $125m . Sale of PRV provides a significant infusion of non-dilutive capital . Sarepta Therapeutics Inc - entered into an agreement to sell its rare pediatric disease priority review voucher . Sarepta Therapeutics - received prv when exondys 51 was approved by U.S. FDA for treatment of patients with duchenne muscular dystrophy amenable to exon 51 skipping .Sarepta Therapeutics Inc - as part of agreement, sarepta will receive an upfront payment of $125m upon closing of transaction.  Full Article

Sarepta Therapeutics Q3 loss per share $1.18
Thursday, 27 Oct 2016 07:00am EDT 

Sarepta Therapeutics Inc : Sarepta Therapeutics announces third quarter 2016 financial results and recent corporate developments . Q3 non-gaap loss per share $0.95 excluding items . Q3 loss per share $1.18 . Sarepta Therapeutics Inc - continue to evaluate sale of priority review voucher as a potential source of non-dilutive financing .Q3 earnings per share view $-1.32 -- Thomson Reuters I/B/E/S.  Full Article

UnitedHealth spokesman confirms plan to cover Sarepta's Exondys 51
Friday, 7 Oct 2016 02:28pm EDT 

UnitedHealth Group Inc : UnitedHealth spokesman confirms plans to cover Sarepta Therapeutics Inc's muscular dystrophy drug Exondys 51. (Reporting by Caroline Humer) ((caroline.humer@thomsonreuters.com;)).  Full Article

Summit's agreement with Sarepta also contains a standstill provision
Tuesday, 4 Oct 2016 07:05am EDT 

Summit Therapeutics Plc : Collaboration agreement with Sarepta also contains a standstill provision - SEC filing .Summit Therapeutics - Believes cash, cash equivalents, certain upfront payments from Sarepta collaboration to be sufficient to fund expenses through 2018.  Full Article

Sarepta and Summit enter into agreement for European rights to utrophin modulator pipeline
Tuesday, 4 Oct 2016 07:00am EDT 

Summit Therapeutics Plc : Summit receives $40 million upfront, with potential future ezutromid-related milestone payments totalling up to $522 million plus royalties . Sarepta also receives option for Latin American rights . As part of agreement, Sarepta also obtains an option to license latin american rights to Summit's utrophin modulator pipeline . If Sarepta elects to exercise option for Latin American rights, co would be entitled to additional fees, milestones and royalties . Sarepta and Summit to share research and development costs . Sarepta also receives option for Latin American rights . Sarepta Therapeutics and summit enter into exclusive license and collaboration agreement for european rights to summit’s utrophin modulator pipeline for the treatment of duchenne muscular dystrophy .Sarepta, co will share specified utrophin modulator-related research and development costs at a 45/55 pct split, respectively.  Full Article

More From Around the Web

Photo

Tourbillon's Karp says Sarepta shares could surge 200 percent

LAS VEGAS Hedge fund manager Jason Karp on Thursday said that shares of Sarepta Therapeutics Inc could climb as much as 200 percent and noted the biotech company could be an attractive takeover candidate.